Open Access

Clinical effects of tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of AVMC and its effects on serum TNF‑α, IL‑18 and IL‑35

  • Authors:
    • Pengliang Xu
    • Lei Ji
    • Shuang Tian
    • Fumei Li
  • View Affiliations

  • Published online on: August 31, 2018     https://doi.org/10.3892/etm.2018.6671
  • Pages: 4070-4074
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Clinical effects of tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of acute viral myocarditis (AVMC) were investigated. Eighty‑six patients with AVMC treated in Dongying City People's Hospital from August 2016 to July 2017 were selected and randomly divided into control group (n=43) and observation group (n=43). Patients in control group were treated with tanshinone ⅡA sodium sulfonate, while those in observation group were treated with trimetazidine and levocarnitine. The curative effect and improvement in clinical symptoms were compared between the two groups of patients, and enzyme‑linked immunosorbent assay (ELISA) was used to detect the levels of heart‑type fatty acid‑binding protein (H‑FABP), creatine kinase‑MB (CK‑MB) and cardiac troponin I (cTnI) in patients after treatment. Besides, the changes in levels of serum tumor necrosis factor‑α (TNF‑α), interleukin (IL)‑18 and IL‑35 were detected via ELISA. The total effective rate of treatment in observation group was significantly higher than that in control group (p<0.05). The improvement in clinical symptoms in observation group was significantly superior to that in control group (p<0.05). After treatment, levels of H‑FABP, CK‑MB and cTnI in observation group were obviously lower than those in control group (p<0.05). At 3, 5 and 7 days after treatment, the levels of TNF‑α and IL‑18 in both groups of patients were decreased compared with those before treatment, but the level of IL‑35 was increased compared with that before treatment, and changes in observation group were more significant than those in control group (p<0.05). Tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine has definite curative effects in the treatment of patients with AVMC, which can alleviate myocardial injury with higher safety, and effectively mitigate the inflammatory response in patients, so it is of great clinical significance.
View References

Related Articles

Journal Cover

November-2018
Volume 16 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu P, Ji L, Tian S and Li F: Clinical effects of tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of AVMC and its effects on serum TNF‑α, IL‑18 and IL‑35. Exp Ther Med 16: 4070-4074, 2018
APA
Xu, P., Ji, L., Tian, S., & Li, F. (2018). Clinical effects of tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of AVMC and its effects on serum TNF‑α, IL‑18 and IL‑35. Experimental and Therapeutic Medicine, 16, 4070-4074. https://doi.org/10.3892/etm.2018.6671
MLA
Xu, P., Ji, L., Tian, S., Li, F."Clinical effects of tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of AVMC and its effects on serum TNF‑α, IL‑18 and IL‑35". Experimental and Therapeutic Medicine 16.5 (2018): 4070-4074.
Chicago
Xu, P., Ji, L., Tian, S., Li, F."Clinical effects of tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of AVMC and its effects on serum TNF‑α, IL‑18 and IL‑35". Experimental and Therapeutic Medicine 16, no. 5 (2018): 4070-4074. https://doi.org/10.3892/etm.2018.6671